CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has published a brochure authored by CVBT co-founder and cardiovascular surgeon Dr. Thomas Stegmann, titled “Holding a Woman’s Heart in My Hands.” The informative booklet addresses the unique medical issues women’s heart disease presents in both diagnosis and treatment, and how angiogenesis—the growth of new blood vessels in the heart—could be a new medical therapy to treat this disease, which kills more than 480,000 women a year, according to the American Heart Association.
“Fifteen years ago, I was holding a woman’s heart in my hands during a coronary bypass operation knowing I needed more advanced medical treatment options to address the special heart issues of a woman. The responsibility I felt towards her and her family led me to the discovery of therapeutic angiogenesis and the development of this drug,” stated Dr. Stegmann. “Women’s heart disease is the number one cause of death in women and existing diagnostics and therapies are not enough. With therapeutic angiogenesis we are introducing a new potential therapy, which I believe can save many lives. In addition, many women don’t view heart disease as a serious health threat and as an active supporter of the American Heart Association Go Red for Women we want to help further educate women about this devastating disease and its treatment options.”
The informative pamphlet will be distributed at the American Heart Association’s Go Red for Women Luncheon, to be held February 27, 2008 at the Four Season’s Hotel in Las Vegas, Nevada. Dr. Stegmann will serve as keynote speaker for the event. The Go Red for Women movement is helping millions of women understand that heart disease, their number one cause of death, is largely preventable and they can take steps to lower their risk. The luncheon will feature activities and topics aimed to educate women about cardiovascular disease, risk factors and their heart-health.
In addition, a copy of the pamphlet is available by e-mailing a request to womensheartdisease@cvbt.com.
CVBT is focused on further developing formulations of the protein drug candidate, human fibroblast growth factor 1 (FGF-1) that Dr. Stegmann discovered for severe coronary heart disease. FGF-1 is a recombinant protein that stimulates new blood vessel growth during a process known as angiogenesis. Once blood perfusion is established in the affected areas, patients with cardiovascular diseases can experience an improved quality of life.
In 2004, Dr. Stegmann published “New Vessels for the Heart: Angiogenesis as New Treatment for Coronary Heart Disease,” which explained his discovery, the first scientific steps and 13-year journey that led to current human clinical trials of FGF-1.
CVBT recently announced that the U.S. Food and Drug Administration (FDA) has allowed the company’s Phase II Clinical Protocol for Coronary Heart Disease trials. The company plans to commence the international study at 30 Medical Centers in the U.S., Canada and Europe.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with human FGF-1 as their active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has three clinical trials underway with drug candidates to treat the following medical indications: severe Coronary Heart Disease (CVBT-141H), dermal wound healing in diabetics (CVBT-141B), and Peripheral Arterial Disease (CVBT-141C).
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.
CardioVascular BioTherapeutics, Inc.
Investor Relations, 702-839-7220
investorrelations@cvbt.com
or
Schwartz Communications
Erin Walsh, 781-684-0770
or
Nicki Polatin, 415-512-0770
cvbt@schwartz-pr.com